EditorialEditorial

Natural killer cells in tumor immunotherapy

Dongyao Wang and Haiming Wei
Cancer Biology & Medicine August 2023, 20 (8) 539-544; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0215

References

  1. 1.↵
    2. Siegel RL,
    3. Miller KD,
    4. Fuchs HE,
    5. Jemal A.
    Cancer statistics, 2022. CA Cancer J Clin. 2022; 72: 7–33.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Zhang C,
    3. Yin J,
    4. Zheng J,
    5. Xiao J,
    6. Hu J,
    7. Su Y, et al.
    EZH2 identifies the precursors of human natural killer cells with trained immunity. Cancer Biol Med. 2021; 18: 1021–39.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    2. Park MD,
    3. Reyes-Torres I,
    4. LeBerichel J,
    5. Hamon P,
    6. LaMarche NM,
    7. Hegde S, et al.
    TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat Immunol. 2023; 24: 792–801.
    OpenUrl
  4. 4.↵
    2. Armand P,
    3. Lesokhin A,
    4. Borrello I,
    5. Timmerman J,
    6. Gutierrez M,
    7. Zhu L, et al.
    A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia. 2021; 35: 777–86.
    OpenUrl
  5. 5.↵
    2. Hasim MS,
    3. Marotel M,
    4. Hodgins JJ,
    5. Vulpis E,
    6. Makinson OJ,
    7. Asif S, et al.
    When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer. Sci Adv. 2022; 8: eabj3286.
  6. 6.↵
    2. Cong J,
    3. Wang X,
    4. Zheng X,
    5. Wang D,
    6. Fu B,
    7. Sun R, et al.
    Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression. Cell Metab. 2018; 28: 243–55.e5.
    OpenUrlPubMed
  7. 7.↵
    2. Zheng X,
    3. Qian Y,
    4. Fu B,
    5. Jiao D,
    6. Jiang Y,
    7. Chen P, et al.
    Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. Nat Immunol. 2019; 20: 1656–67.
    OpenUrlPubMed
  8. 8.↵
    2. Orange JS.
    Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol. 2008; 8: 713–25.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. Zheng X,
    3. Hou Z,
    4. Qian Y,
    5. Zhang Y,
    6. Cui Q,
    7. Wang X, et al.
    Tumors evade immune cytotoxicity by altering the surface topology of NK cells. Nat Immunol. 2023; 24: 802–13.
    OpenUrl
  10. 10.↵
    2. Knelson EH,
    3. Ivanova EV,
    4. Tarannum M,
    5. Campisi M,
    6. Lizotte PH,
    7. Booker MA, et al.
    Activation of tumor-cell STING primes NK-cell therapy. Cancer Immunol Res. 2022; 10: 947–61.
    OpenUrl
  11. 11.↵
    2. Li F,
    3. Liu S.
    Focusing on NK cells and ADCC: a promising immunotherapy approach in targeted therapy for HER2-positive breast cancer. Front Immunol. 2022; 13: 1083462.
  12. 12.↵
    2. Vyas M,
    3. Peigney D,
    4. Demehri S.
    Extracellular matrix-natural killer cell interactome: an uncharted territory in health and disease. Curr Opin Immunol. 2022; 78: 102246.
  13. 13.↵
    2. Rossi GR,
    3. Trindade ES,
    4. Souza-Fonseca-Guimaraes F.
    Tumor microenvironment-associated extracellular matrix components regulate NK cell function. Front Immunol. 2020; 11: 73.
    OpenUrl
  14. 14.↵
    2. Sun X,
    3. Wu B,
    4. Chiang HC,
    5. Deng H,
    6. Zhang X,
    7. Xiong W, et al.
    Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature. 2021; 599: 673–8.
    OpenUrl
  15. 15.↵
    2. Wang D,
    3. Sun Z,
    4. Zhu X,
    5. Zheng X,
    6. Zhou Y,
    7. Lu Y, et al.
    GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT. Blood. 2022; 140: 2788–804.
    OpenUrl
  16. 16.↵
    2. Vago L,
    3. Gojo I.
    Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020; 130: 1552–64.
    OpenUrlCrossRef
  17. 17.↵
    2. Xue W,
    3. Zhang M.
    Updating targets for natural killer/T-cell lymphoma immunotherapy. Cancer Biol Med. 2021; 18: 52–62.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Liu E,
    3. Marin D,
    4. Banerjee P,
    5. Macapinlac HA,
    6. Thompson P,
    7. Basar R, et al.
    Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020; 382: 545–53.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Xie G,
    3. Dong H,
    4. Liang Y,
    5. Ham JD,
    6. Rizwan R,
    7. Chen J.
    CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020; 59: 102975.
  20. 20.↵
    2. Li Y,
    3. Basar R,
    4. Wang G,
    5. Liu E,
    6. Moyes JS,
    7. Li L, et al.
    KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022; 28: 2133–44.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section